Article

Potent Anti-Delta Effect By a Booster Third-Dose of UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide Vaccine

2021-10-18

Abstract excerpt

SARS-CoV-2 breakthrough infection occurs due to waning immunity time-to-vaccine, to which the globally-dominant, highly-contagious Delta variant is behind the scene. In the primary 2-dose and booster series of clinical Phase-1 trial, UB-612 vaccine, which contains S1-RBD and synthetic Th/CTL peptide pool for activation of humoral and T-cell immunity, induces substantial, prolonged viral-neutralizing antibodies tha...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cfdf6c45-4265-5469-9194-8b94567f65e6
DOI: 10.21203/rs.3.rs-944205/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Potent Anti-Delta Effect By a Booster Third-Dose of UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide VaccineDOI 10.21203/rs.3.rs-944205/v1Read

UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of ConcernSemantic proximity Read

Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpointSemantic proximity Read

High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike AntigensSemantic proximity Read

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trialSemantic proximity Read

Preclinical Immunological Evaluation of an Intradermally Administered Heterologous Vaccine Against SARS-CoV-2 VariantsSemantic proximity Read

Age Dependent Reduction of Neutralization Capacities Against Delta Variant Five Months Post-Vaccination (BNT162b2)Semantic proximity Read

S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primatesSemantic proximity Read

Immunogenicity of BNT162b2 vaccine Against the Alpha and Delta Variants in Immunocompromised PatientsSemantic proximity Read

Should the world collaborate imminently to develop neglected live‐attenuated vaccines for COVID‐19?Semantic proximity Read

SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concernSemantic proximity Read

Evaluation of the safety and immunogenicity of fractional intradermal COVID-19 vaccines as a booster: A pilot studySemantic proximity Read

Development of an RBD-Fc fusion vaccine for COVID-19Semantic proximity Read